PTCT PTC Therapeutics RESULTS: Q2, Q2 product REV $238,819,238.819M, Q2 operating expenses $211.542M, Q2 Net Income $83.496M, Q2 Operating I
PTCT PTC Therapeutics RESULTS: Q2, Q2 product REV $238,819,238.819M, Q2 operating expenses $211.542M, Q2 Net Income $83.496M, Q2 Operating Income $148.977M, Q2 basic EPS $1.01, PTC Therapeutics Earnings Notes:, Outlook FY REV $1,180-1.280B, Total product REV guidance raised to $850 to $950M for FY 2026
PTCT PTC Therapeutics RESULTS: Q2, Q2 product REV $238,819,238.819M, Q2 operating expenses $211.542M, Q2 Net Income $83.496M, Q2 Operating Income $148.977M, Q2 basic EPS $1.01, PTC Therapeutics Earnings Notes:, Outlook FY REV $1,180-1.280B, Total product REV guidance raised to $850 to $950M for FY 2026